WO2012005605A1 - A combination composition comprising ibuprofen and paracetamol - Google Patents
A combination composition comprising ibuprofen and paracetamol Download PDFInfo
- Publication number
- WO2012005605A1 WO2012005605A1 PCT/NZ2011/000117 NZ2011000117W WO2012005605A1 WO 2012005605 A1 WO2012005605 A1 WO 2012005605A1 NZ 2011000117 W NZ2011000117 W NZ 2011000117W WO 2012005605 A1 WO2012005605 A1 WO 2012005605A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- approximately
- ibuprofen
- paracetamol
- composition
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Definitions
- This invention relates to a combination composition comprising paracetamol and ibuprofen.
- a particularly preferred embodiment of the invention relates to a combination composition comprising these as active ingredients for use in relieving pain and/or inflammation.
- Combinations of paracetamol and ibuprofen are known, for example as relatively low dose tablets having 150 mg ibuprofen and 500 mg.
- a medication particularly one which can be administered intravenously in a hospital environment, which delivers higher doses of ibuprofen to provide pain relief in cases of severe or extreme pain. It is an object of one embodiment of the present invention to go at least some way towards facilitating this.
- references in this specification to an adult mean a person weighing 50 kg or more.
- references in this specification to a child mean a person weighing less than 50 kg.
- compositions for providing relief for pain and/or inflammation having ibuprofen and paracetamol in combination for delivering to a human at each dose:
- composition for delivering to the human (preferably an adult) at each dose approximately 400 mg ibuprofen and approximately 1 ,000 mg paracetamol.
- composition for delivering to the human (preferably an adult) at each dose approximately 600 mg ibuprofen and approximately 1 ,000 mg paracetamol.
- composition for delivering to a child at each dose approximately 200 mg ibuprofen and approximately 500 mg paracetamol.
- composition for delivering to a child at each dose approximately 300 mg ibuprofen and approximately 500 mg paracetamol.
- composition is for delivering the ibuprofen and paracetamol to the human (eg a child or adult) intravenously.
- composition is in the form of a solution.
- composition is in the form of a suspension.
- a further aspect of the invention involves the use of ibuprofen and paracetamol in the manufacture of a medicament for treating pain and/or inflammation in a human, the medicament having:
- the medicament has approximately 400 mg ibuprofen and approximately 1 ,000 mg paracetamol. In this instance the medicament may be for treating an adult.
- the medicament has approximately 600 mg ibuprofen and approximately 1 ,000 mg paracetamol.
- the medicament may be for treating an adult.
- the medicament is for treating a child and has approximately 200 mg ibuprofen and approximately 500 mg paracetamol.
- the medicament is for treating a child and has approximately 300 mg ibuprofen and approximately 500 mg paracetamol.
- the medicament is for intravenous administration.
- composition is in the form of a solution.
- composition is in the form of a suspension.
- a method of treating a human to relieve pain and/or inflammation comprising administering to the human: a) approximately 375 mg to approximately 425 mg ibuprofen,
- approximately 400 mg ibuprofen and approximately 1 ,000 mg paracetamol are administered to the human per dose.
- the human is preferably an adult.
- approximately 600 mg ibuprofen and approximately 1,000 mg paracetamol are administered to the human per dose.
- the human is preferably an adult.
- approximately 200 mg ibuprofen and approximately 500 mg paracetamol are administered to a child per dose.
- approximately 300 mg ibuprofen and approximately 500 mg paracetamol are administered to a child per dose.
- composition is administered to the human (eg an adult or child) intravenously.
- composition is in the form of a solution.
- composition is in the form of a suspension.
- an intravenous solution for use in treating severe pain in human patients.
- the solution is a combination medication comprising ibuprofen, paracetamol, purified water and suitable excipients as will be known to those with ordinary skills in the art of formulating intravenous medicines.
- the excipients may be standard and may include one or more of suspending agents, viscosity regulating agents, buffering agents, wetting agents, preservatives, sweetening agents, flavouring agents and solvents.
- Example 1 Example 2
- Example 3 Example 4 mg/ 100ml vial mg/ 100ml vial mg/ 50ml vial mg/ 50ml vial
- composition to composition 100 ml
- All of the above infusion solutions are for delivery to a patient as a full dose, for example in each case the patient receives the complete vial contents as a 15 minute infusion every 6 hours.
- Examples 1 , 2 and 5 are each an adult dose and Examples 3, 4 and 6 are each a child dose. In the case of very young or small children only part of the vial contents of Examples 3, 4 and 6 may be dosed, commensurate with instructions from the prescribing physician.
- Paracetamol at 4,000 mg per 24 hour period taken in 4 doses of 1,000 mg every 6 hours, has long been considered sufficient for relieving low level pain but for many patients suffering significant pain, for example in some post-operative situations, it is not sufficient. However it is generally not advisable to dose paracetamol at more than 1 ,000 mg per dose or at more than 4,000 mg per 24 hour period, because to do so can lead to undesirable side effects.
- ibuprofen It is known to treat severe pain with ibuprofen in doses of 800 mg every 8 hours. However, doses as high as 800 mg can lead to undesirable side effects, for example adverse cardio renal conditions, thrombotic risks and gastrointestinal bleeding. Reducing the amount of ibuprofen at each dosing event may reduce the risk of side affects but at the same time may provide substantially less pain relief.
- a combination medicine comprising 600 mg or 400 mg ibuprofen, plus 1 ,000 mg paracetamol, for use every 6 hours, provides adequate pain relief for some patients that would otherwise take 800 mg ibuprofen every 8 hours.
- ibuprofen and paracetamol are specifically referred to in this specification, suitable other pharmaceutically acceptable forms of these two actives (eg salts, etc) may also be used and are intended to be embraced in the claims by references to the actives per se, with the weight amounts adjusted accordingly.
- suitable other pharmaceutically acceptable forms of these two actives eg salts, etc
- sufficient quantity may be included to meet the desired amount of the compound per se (eg, 200 mg ibuprofen corresponds with 368 mg ibuprofen arginine, or 342 mg ibuprofen lysinate).
- a reference to 200 mg ibuprofen may be construed as sufficient to embrace the therapeutically equivalent amount of ibuprofen arginine or ibuprofen lysinate.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011274652A AU2011274652B2 (en) | 2010-07-07 | 2011-06-21 | A combination composition comprising ibuprofen and paracetamol |
SG2012093183A SG186388A1 (en) | 2010-07-07 | 2011-06-21 | A combination composition comprising ibuprofen and paracetamol |
NZ60400911A NZ604009A (en) | 2010-07-07 | 2011-06-21 | A combination composition comprising ibuprofen and paracetamol |
ZA2012/08210A ZA201208210B (en) | 2010-07-07 | 2012-12-06 | A combination composition comprising ibuprofen and paracetamal |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ58666110 | 2010-07-07 | ||
NZ586661 | 2010-07-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012005605A1 true WO2012005605A1 (en) | 2012-01-12 |
Family
ID=45441395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NZ2011/000117 WO2012005605A1 (en) | 2010-07-07 | 2011-06-21 | A combination composition comprising ibuprofen and paracetamol |
Country Status (6)
Country | Link |
---|---|
AU (1) | AU2011274652B2 (en) |
MY (1) | MY164112A (en) |
NZ (1) | NZ604009A (en) |
SG (1) | SG186388A1 (en) |
WO (1) | WO2012005605A1 (en) |
ZA (1) | ZA201208210B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012060719A1 (en) * | 2010-11-04 | 2012-05-10 | Aft Pharmaceuticals Limited | A combination composition |
CN103565733A (en) * | 2012-07-31 | 2014-02-12 | 南京帝易医药科技有限公司 | Ibuprofen sodium chloride injection preparation with pH of 6.0-6.5, and preparation method thereof |
US11197830B2 (en) | 2019-02-27 | 2021-12-14 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetaminophen and ibuprofen |
WO2023281089A2 (en) | 2021-07-08 | 2023-01-12 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising naproxen and paracetamol |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080200549A1 (en) * | 2004-07-07 | 2008-08-21 | Aft Pharmaceuticals Limited | Pharmaceutical composition of ibuprofen and paracetamol and methods of using the same |
US20090264530A1 (en) * | 2008-04-16 | 2009-10-22 | Nickell Robert P | Combined nsaid and acetaminophen formulation and method |
-
2011
- 2011-06-21 WO PCT/NZ2011/000117 patent/WO2012005605A1/en active Application Filing
- 2011-06-21 AU AU2011274652A patent/AU2011274652B2/en active Active
- 2011-06-21 NZ NZ60400911A patent/NZ604009A/en unknown
- 2011-06-21 SG SG2012093183A patent/SG186388A1/en unknown
- 2011-06-21 MY MYPI2012005317A patent/MY164112A/en unknown
-
2012
- 2012-12-06 ZA ZA2012/08210A patent/ZA201208210B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080200549A1 (en) * | 2004-07-07 | 2008-08-21 | Aft Pharmaceuticals Limited | Pharmaceutical composition of ibuprofen and paracetamol and methods of using the same |
US20090264530A1 (en) * | 2008-04-16 | 2009-10-22 | Nickell Robert P | Combined nsaid and acetaminophen formulation and method |
Non-Patent Citations (2)
Title |
---|
MEHLISCH, D.R. ET AL.: "Comparison of the Analgesic Efficacy of Concurrent Ibuprofen and Paracetamol With Ibuprofen or Paracetamol Alone in the Management of Moderate to Severe Acute Postoperative Dental Pain in Adolescents and Adults: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Dose, Two Center,", CLINICAL THERAPEUTICS, vol. 32, no. 5, May 2010 (2010-05-01), pages 882 - 895, XP027067923, DOI: doi:10.1016/j.clinthera.2010.04.022 * |
SNIEZEK, P. J. ET AL.: "A Randomizes Controlled Trial Comparing Acetaminophen, Acetaminophan and Ibuprofen, and Acetaminophen and Codeine for Postoperative Pain Relief After Mohs Surgery and Cutaneous Reconstruction.", DERMATOLOGIC SURGERY, vol. 37, no. 7, July 2011 (2011-07-01), pages 1007 - 1013 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012060719A1 (en) * | 2010-11-04 | 2012-05-10 | Aft Pharmaceuticals Limited | A combination composition |
AU2011324137B2 (en) * | 2010-11-04 | 2015-05-07 | Aft Pharmaceuticals Limited | A combination composition |
US11446266B2 (en) | 2010-11-04 | 2022-09-20 | Aft Pharmaceuticals Limited | Combination composition |
US11896567B2 (en) | 2010-11-04 | 2024-02-13 | Aft Pharmaceuticals Limited | Combination composition |
CN103565733A (en) * | 2012-07-31 | 2014-02-12 | 南京帝易医药科技有限公司 | Ibuprofen sodium chloride injection preparation with pH of 6.0-6.5, and preparation method thereof |
US11197830B2 (en) | 2019-02-27 | 2021-12-14 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetaminophen and ibuprofen |
US11534407B2 (en) | 2019-02-27 | 2022-12-27 | Aft Pharmaceuticals Limited | Pharmaceutical compostion containing acetominophen and ibuprofen |
US11872317B2 (en) | 2019-02-27 | 2024-01-16 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetominophen and ibuprofen |
WO2023281089A2 (en) | 2021-07-08 | 2023-01-12 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising naproxen and paracetamol |
Also Published As
Publication number | Publication date |
---|---|
SG186388A1 (en) | 2013-01-30 |
AU2011274652A1 (en) | 2013-01-10 |
ZA201208210B (en) | 2014-04-30 |
AU2011274652B2 (en) | 2013-08-15 |
MY164112A (en) | 2017-11-30 |
NZ604009A (en) | 2015-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11896567B2 (en) | Combination composition | |
JP6738376B2 (en) | Method of treating bendamustine-responsive symptoms in patients in need of reduced dosing volume | |
AU2010335594B2 (en) | Synergistic antiviral composition and use thereof | |
AU2011274652B2 (en) | A combination composition comprising ibuprofen and paracetamol | |
CN110869003A (en) | Preservative-free solid-dosage vigabatrin pharmaceutical composition | |
CA2408797A1 (en) | Treatment of breast cancer | |
AU2017305661B2 (en) | New use of N,N-bis-2-mercaptoethyl isophthalamide | |
KR20120089444A (en) | Treating critically ill patients with intravenous ibuprofen | |
WO2012156502A2 (en) | Two component mouth rinse preparation | |
CN114096269A (en) | High concentration insulin formulations | |
WO2020155507A1 (en) | Preservative-free vigabatrin pharmaceutical composition in solid dosage form | |
WO2014150318A1 (en) | Therapeutic agent for enhancing mitochondrial function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11803858 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2012/15828 Country of ref document: TR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011274652 Country of ref document: AU Date of ref document: 20110621 Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11803858 Country of ref document: EP Kind code of ref document: A1 |